Sacubitril/Valsartan in Left Ventricular Assist Device Recipients
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of
sacubitril/valsartan compared with standard of care used for treating BP in patients that
have been implanted with the Heart Mate 3 LVAD (events of special interest - all cause death,
right ventricular failure, bleeding events, deterioration in renal function, hyperkalemia,
symptomatic hypotension).
Phase:
Phase 4
Details
Lead Sponsor:
University of Zagreb
Treatments:
Enalapril Enalaprilat LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan